Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

NCT04742738 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 (Healthy Volunteers)

Interventions

BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1
BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1
OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1
BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2
BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2
OTHER: Normal saline (0.9% sodium chloride solution)- Stage 2

Sponsor

SK Bioscience Co., Ltd.

Collaborators

[object Object]